Summary
The pharmacovigilance market was valued at $8,202.49 million in 2024 and is estimated to reach $26,212.81 million by 2034, exhibiting a CAGR of 12.3% from 2025 to 2034.
The process of detection, understanding, assessment and prevention of adverse effects associated with drugs is termed as pharmacovigilance. It is important for ensuring the efficacy and safety of pharmaceutical products. It is majorly used in healthcare and pharmaceutical sectors across the globe.
Rise in incidences of adverse drug reactions, rise in cases of drug toxicity, and surge in complexity of drug development makes way for the increase in demand for pharmacovigilance. In addition, rise in biologics and personalized medicines also boosts the growth of the pharmacovigilance market. Moreover, rise in drug developments for rare diseases increases the need for drug safety assessments, which fosters the pharmacovigilance market growth. However, rise in associated costs and surge in complexity of pharmacovigilance activities limits the market growth. The small and mid-sized sectors are budget-conscious and hence replan the investment in pharmacovigilance services. Also, shortage of skilled professionals in pharmacovigilance sector is another factor limiting the growth of the market.
Nevertheless, outsourcing pharmacovigilance services to contract research organizations and surge in advancements in technology, which includes usage of artificial intelligence, cloud-based platforms, and automation in pharmacovigilance sector is projected to boost the growth of the pharmacovigilance market during the forecast period.
The pharmacovigilance market is segmented into type, process flow, deployment, therapeutic area, and region. On the basis of type, it is bifurcated into services and software. The service segment is further divided into spontaneous reporting, intensified ADR reporting, targeted spontaneous reporting, and others**. On the basis of process flow, the market is segregated into pre-marketing and post-marketing. market is categorized into in-house and contract outsourcing. On the basis of therapeutic area, the market is classified into oncology, neurology**, cardiology, respiratory system and others. Region-wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Accenture**, Cognizant, Oracle Corporation, Labcorp, ICON Plc., Capgemini, Clario, Wipro Limited, IQVIA, and Parexel. The key players operating in the market have adopted collaboration, and partnership as their key strategies to expand their product portfolio.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of pharmacovigilance market analysis from 2024 to 2034 to identify the prevailing pharmacovigilance market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the pharmacovigilance market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global pharmacovigilance market trends, key players, market segments, application areas, and market growth strategies.
Additional benefits you will get with this purchase are:
● Quarterly Update and* (only available with a corporate license, on listed price)
● 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
● Free Upcoming Version on the Purchase of Five and Enterprise User License.
● 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
● 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
● Free data Pack on the Five and Enterprise User License. (Excel version of the report)
● Free Updated report if the report is 6-12 months old or older.
● 24-hour priority response*
● Free industry updates and white papers. Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
● Additional company profiles with specific to client's interest
● Expanded list for Company Profiles
● Historic market data
Key Market Segments
By Type
● Services
○ Type
○ Spontaneous Reporting
○ Intensified ADR Reporting
○ Targeted Spontaneous Reporting
○ Others
● Software
By Process Flow
● Pre-marketing
● Post-marketing
By Deployment
● In House
● Contract Outsourcing
By Therapeutic Area
● Neurology
● Cardiology
● Respiratory Systems
● Others
● Oncology
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ France
○ UK
○ Italy
○ Spain
○ Rest of Europe
● Asia-Pacific
○ Japan
○ China
○ India
○ Australia
○ South Korea
○ Rest of Asia-Pacific
● LAMEA○ Brazil
○ Saudi Arabia
○ South Africa
○ Rest of LAMEA
● Key Market Players
○ Cognizant
○ Oracle Corporation
○ labcorp
○ ICON Plc
○ Capgemini
○ Wipro Limited
○ IQVIA
○ Parexel
○ Clario
○ Accenture
ページTOPに戻る
Table of Contents
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. High threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rising Volume of Adverse Drug Reactions (ADRs) and Regulatory Pressure
3.4.1.2. Growth in Clinical Trials and New Drug Approvals
3.4.1.3. Integration of AI and Automation in Drug Safety Monitoring
3.4.2. Restraints
3.4.2.1. High Cost and Complexity of Implementation
3.4.3. Opportunities
3.4.3.1. Expansion in Emerging Markets and Pharmacovigilance Outsourcing
CHAPTER 4: PHARMACOVIGILANCE MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Services
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. Services Pharmacovigilance Market by Type
4.2.4.1. Spontaneous Reporting Market size and forecast, by region
4.2.4.2. Spontaneous Reporting Market size and forecast, by country
4.2.4.3. Intensified ADR Reporting Market size and forecast, by region
4.2.4.4. Intensified ADR Reporting Market size and forecast, by country
4.2.4.5. Targeted Spontaneous Reporting Market size and forecast, by region
4.2.4.6. Targeted Spontaneous Reporting Market size and forecast, by country
4.2.4.7. Others Market size and forecast, by region
4.2.4.8. Others Market size and forecast, by country
4.3. Software
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: PHARMACOVIGILANCE MARKET, BY PROCESS FLOW
5.1. Overview
5.1.1. Market size and forecast
5.2. Pre-marketing
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Post-marketing
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: PHARMACOVIGILANCE MARKET, BY DEPLOYMENT
6.1. Overview
6.1.1. Market size and forecast
6.2. In House
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Contract Outsourcing
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: PHARMACOVIGILANCE MARKET, BY THERAPEUTIC AREA
7.1. Overview
7.1.1. Market size and forecast
7.2. Oncology
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Neurology
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Cardiology
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
7.5. Respiratory Systems
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by region
7.5.3. Market share analysis by country
7.6. Others
7.6.1. Key market trends, growth factors and opportunities
7.6.2. Market size and forecast, by region
7.6.3. Market share analysis by country
CHAPTER 8: PHARMACOVIGILANCE MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Type
8.2.2.1. North America Services Pharmacovigilance Market by Type
8.2.3. Market size and forecast, by Process Flow
8.2.4. Market size and forecast, by Deployment
8.2.5. Market size and forecast, by Therapeutic Area
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Type
8.2.6.1.1.1. U.S. Services Pharmacovigilance Market by Type
8.2.6.1.2. Market size and forecast, by Process Flow
8.2.6.1.3. Market size and forecast, by Deployment
8.2.6.1.4. Market size and forecast, by Therapeutic Area
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Type
8.2.6.2.1.1. Canada Services Pharmacovigilance Market by Type
8.2.6.2.2. Market size and forecast, by Process Flow
8.2.6.2.3. Market size and forecast, by Deployment
8.2.6.2.4. Market size and forecast, by Therapeutic Area
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Type
8.2.6.3.1.1. Mexico Services Pharmacovigilance Market by Type
8.2.6.3.2. Market size and forecast, by Process Flow
8.2.6.3.3. Market size and forecast, by Deployment
8.2.6.3.4. Market size and forecast, by Therapeutic Area
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Type
8.3.2.1. Europe Services Pharmacovigilance Market by Type
8.3.3. Market size and forecast, by Process Flow
8.3.4. Market size and forecast, by Deployment
8.3.5. Market size and forecast, by Therapeutic Area
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Type
8.3.6.1.1.1. Germany Services Pharmacovigilance Market by Type
8.3.6.1.2. Market size and forecast, by Process Flow
8.3.6.1.3. Market size and forecast, by Deployment
8.3.6.1.4. Market size and forecast, by Therapeutic Area
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Type
8.3.6.2.1.1. France Services Pharmacovigilance Market by Type
8.3.6.2.2. Market size and forecast, by Process Flow
8.3.6.2.3. Market size and forecast, by Deployment
8.3.6.2.4. Market size and forecast, by Therapeutic Area
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Type
8.3.6.3.1.1. UK Services Pharmacovigilance Market by Type
8.3.6.3.2. Market size and forecast, by Process Flow
8.3.6.3.3. Market size and forecast, by Deployment
8.3.6.3.4. Market size and forecast, by Therapeutic Area
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Type
8.3.6.4.1.1. Italy Services Pharmacovigilance Market by Type
8.3.6.4.2. Market size and forecast, by Process Flow
8.3.6.4.3. Market size and forecast, by Deployment
8.3.6.4.4. Market size and forecast, by Therapeutic Area
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Type
8.3.6.5.1.1. Spain Services Pharmacovigilance Market by Type
8.3.6.5.2. Market size and forecast, by Process Flow
8.3.6.5.3. Market size and forecast, by Deployment
8.3.6.5.4. Market size and forecast, by Therapeutic Area
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Type
8.3.6.6.1.1. Rest of Europe Services Pharmacovigilance Market by Type
8.3.6.6.2. Market size and forecast, by Process Flow
8.3.6.6.3. Market size and forecast, by Deployment
8.3.6.6.4. Market size and forecast, by Therapeutic Area
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Type
8.4.2.1. Asia-Pacific Services Pharmacovigilance Market by Type
8.4.3. Market size and forecast, by Process Flow
8.4.4. Market size and forecast, by Deployment
8.4.5. Market size and forecast, by Therapeutic Area
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Type
8.4.6.1.1.1. Japan Services Pharmacovigilance Market by Type
8.4.6.1.2. Market size and forecast, by Process Flow
8.4.6.1.3. Market size and forecast, by Deployment
8.4.6.1.4. Market size and forecast, by Therapeutic Area
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Type
8.4.6.2.1.1. China Services Pharmacovigilance Market by Type
8.4.6.2.2. Market size and forecast, by Process Flow
8.4.6.2.3. Market size and forecast, by Deployment
8.4.6.2.4. Market size and forecast, by Therapeutic Area
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Type
8.4.6.3.1.1. India Services Pharmacovigilance Market by Type
8.4.6.3.2. Market size and forecast, by Process Flow
8.4.6.3.3. Market size and forecast, by Deployment
8.4.6.3.4. Market size and forecast, by Therapeutic Area
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Type
8.4.6.4.1.1. Australia Services Pharmacovigilance Market by Type
8.4.6.4.2. Market size and forecast, by Process Flow
8.4.6.4.3. Market size and forecast, by Deployment
8.4.6.4.4. Market size and forecast, by Therapeutic Area
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Type
8.4.6.5.1.1. South Korea Services Pharmacovigilance Market by Type
8.4.6.5.2. Market size and forecast, by Process Flow
8.4.6.5.3. Market size and forecast, by Deployment
8.4.6.5.4. Market size and forecast, by Therapeutic Area
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Type
8.4.6.6.1.1. Rest of Asia-Pacific Services Pharmacovigilance Market by Type
8.4.6.6.2. Market size and forecast, by Process Flow
8.4.6.6.3. Market size and forecast, by Deployment
8.4.6.6.4. Market size and forecast, by Therapeutic Area
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Type
8.5.2.1. LAMEA Services Pharmacovigilance Market by Type
8.5.3. Market size and forecast, by Process Flow
8.5.4. Market size and forecast, by Deployment
8.5.5. Market size and forecast, by Therapeutic Area
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Type
8.5.6.1.1.1. Brazil Services Pharmacovigilance Market by Type
8.5.6.1.2. Market size and forecast, by Process Flow
8.5.6.1.3. Market size and forecast, by Deployment
8.5.6.1.4. Market size and forecast, by Therapeutic Area
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Type
8.5.6.2.1.1. Saudi Arabia Services Pharmacovigilance Market by Type
8.5.6.2.2. Market size and forecast, by Process Flow
8.5.6.2.3. Market size and forecast, by Deployment
8.5.6.2.4. Market size and forecast, by Therapeutic Area
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Type
8.5.6.3.1.1. South Africa Services Pharmacovigilance Market by Type
8.5.6.3.2. Market size and forecast, by Process Flow
8.5.6.3.3. Market size and forecast, by Deployment
8.5.6.3.4. Market size and forecast, by Therapeutic Area
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Type
8.5.6.4.1.1. Rest of LAMEA Services Pharmacovigilance Market by Type
8.5.6.4.2. Market size and forecast, by Process Flow
8.5.6.4.3. Market size and forecast, by Deployment
8.5.6.4.4. Market size and forecast, by Therapeutic Area
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product mapping of top 10 player
9.4. Competitive dashboard
9.5. Competitive heatmap
9.6. Top player positioning, 2024
CHAPTER 10: COMPANY PROFILES
10.1. Accenture
10.1.1. Company overview
10.1.2. Key executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.2. Cognizant
10.2.1. Company overview
10.2.2. Key executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Oracle Corporation
10.3.1. Company overview
10.3.2. Key executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.3.6. Business performance
10.4. labcorp
10.4.1. Company overview
10.4.2. Key executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Wipro Limited
10.5.1. Company overview
10.5.2. Key executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.6. ICON Plc
10.6.1. Company overview
10.6.2. Key executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.6.7. Key strategic moves and developments
10.7. Capgemini
10.7.1. Company overview
10.7.2. Key executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.8. Clario
10.8.1. Company overview
10.8.2. Key executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.9. IQVIA
10.9.1. Company overview
10.9.2. Key executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.9.7. Key strategic moves and developments
10.10. Parexel
10.10.1. Company overview
10.10.2. Key executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Key strategic moves and developments
